 |  |
| ABX | ||
| 985.063 | ||
| -2.6790 | -0.0027% | |
| BISNIS-27 | ||
| 596.902 | ||
| -1.3880 | -0.0023% | |
| DBX | ||
| 1,999.338 | ||
| 1.9070 | 0.0010% | |
| ECONOMIC30 | ||
| 135.810 | ||
| 0.1700 | 0.0013% | |
| ESGQKEHATI | ||
| 141.311 | ||
| -0.1220 | -0.0009% | |
| ESGSKEHATI | ||
| 141.355 | ||
| -0.1520 | -0.0011% | |
| I-GRADE | ||
| 240.206 | ||
| -0.4190 | -0.0017% | |
| AUDRP | ||
| 10,386.600 | ||
| -50.2000 | -0.4810% | |
| EURRP | ||
| 16,894.000 | ||
| -68.5000 | -0.4038% | |
| JPYRP | ||
| 103.948 | ||
| -0.4140 | -0.3967% | |
| SINRP | ||
| 11,856.400 | ||
| -36.5000 | -0.3069% | |
| USDRP | ||
| 15,507.000 | ||
| -68.0000 | -0.4366% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
